Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Respiratory syncytial virus infections in children 0-24 months of age in the community.

Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Mertsola J, Waris M, Peltola V.

J Infect. 2019 Sep 12. pii: S0163-4453(19)30273-7. doi: 10.1016/j.jinf.2019.09.002. [Epub ahead of print]

PMID:
31521741
2.

Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015.

Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim D, Greve-Isdahl M, Wehlin L, Ljungman M, Fry NK, Markey K, He Q.

Euro Surveill. 2019 Feb;24(7). doi: 10.2807/1560-7917.ES.2019.24.7.1700832.

3.

Prenatal Maternal Psychological Distress and Offspring Risk for Recurrent Respiratory Infections.

Korhonen LS, Karlsson L, Scheinin NM, Korja R, Tolvanen M, Mertsola J, Peltola V, Karlsson H.

J Pediatr. 2019 May;208:229-235.e1. doi: 10.1016/j.jpeds.2018.12.050. Epub 2019 Feb 2.

PMID:
30723014
4.

High prevalence of currently circulating Bordetella pertussis isolates not producing vaccine antigen pertactin in Slovenia.

Kastrin T, Barkoff AM, Paragi M, Vitek MG, Mertsola J, He Q.

Clin Microbiol Infect. 2019 Feb;25(2):258-260. doi: 10.1016/j.cmi.2018.10.005. Epub 2018 Oct 26. No abstract available.

PMID:
30691616
5.

Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015.

Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim DF, Greve-Isdahl M, Wehlin L, Ljungman M, Fry NK, Markey K, Auranen K, He Q.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01998-17. doi: 10.1128/JCM.01998-17. Print 2018 May.

6.

Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.

Lönnqvist E, Barkoff AM, Mertsola J, He Q.

J Glob Antimicrob Resist. 2018 Sep;14:12-16. doi: 10.1016/j.jgar.2018.02.012. Epub 2018 Feb 24.

PMID:
29486357
7.

A rapid lateral flow immunoassay for serological diagnosis of pertussis.

Salminen T, Knuutila A, Barkoff AM, Mertsola J, He Q.

Vaccine. 2018 Mar 7;36(11):1429-1434. doi: 10.1016/j.vaccine.2018.01.064. Epub 2018 Feb 6.

PMID:
29426656
8.

Decreased incidence of pertussis in young adults after the introduction of booster vaccine in military conscripts: Epidemiological analyses of pertussis in Finland, 1995-2015.

Zöldi V, Sane J, Nohynek H, Virkki M, Hannila-Handelberg T, Mertsola J.

Vaccine. 2017 Sep 18;35(39):5249-5255. doi: 10.1016/j.vaccine.2017.08.008. Epub 2017 Aug 18.

PMID:
28823620
9.

Polymorphisms of Mannose-binding Lectin and Toll-like Receptors 2, 3, 4, 7 and 8 and the Risk of Respiratory Infections and Acute Otitis Media in Children.

Toivonen L, Vuononvirta J, Mertsola J, Waris M, He Q, Peltola V.

Pediatr Infect Dis J. 2017 May;36(5):e114-e122. doi: 10.1097/INF.0000000000001479.

PMID:
28403045
10.

Rapid detection of functional gene polymorphisms of TLRs and IL-17 using high resolution melting analysis.

Teräsjärvi J, Hakanen A, Korppi M, Nuolivirta K, Gröndahl-Yli-Hannuksela K, Mertsola J, Peltola V, He Q.

Sci Rep. 2017 Feb 2;7:41522. doi: 10.1038/srep41522.

11.

Association of MBL2, TLR1, TLR2 and TLR6 Polymorphisms With Production of IFN-γ and IL-12 in BCG Osteitis Survivors R1.

Pöyhönen L, Kröger L, Huhtala H, Mäkinen J, Nuolivirta K, Mertsola J, He Q, Korppi M.

Pediatr Infect Dis J. 2017 Feb;36(2):135-139. doi: 10.1097/INF.0000000000001375.

PMID:
27755461
12.

Rhinovirus Infections in the First 2 Years of Life.

Toivonen L, Schuez-Havupalo L, Karppinen S, Teros-Jaakkola T, Rulli M, Mertsola J, Waris M, Peltola V.

Pediatrics. 2016 Sep;138(3). pii: e20161309. doi: 10.1542/peds.2016-1309.

13.

Burden of Recurrent Respiratory Tract Infections in Children: A Prospective Cohort Study.

Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Vuononvirta J, Mertsola J, He Q, Waris M, Peltola V.

Pediatr Infect Dis J. 2016 Dec;35(12):e362-e369.

PMID:
27455443
14.

Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.

Gröndahl-Yli-Hannuksela K, Vahlberg T, Ilonen J, Mertsola J, He Q.

Immunogenetics. 2016 Oct;68(9):733-41. doi: 10.1007/s00251-016-0923-0. Epub 2016 Jun 10.

PMID:
27282930
15.

Interferon-gamma-dependent Immunity in Bacillus Calmette-Guérin Vaccine Osteitis Survivors.

Pöyhönen L, Kröger L, Huhtala H, Mäkinen J, Mertsola J, Martinez-Barricarte R, Casanova JL, Bustamante J, He Q, Korppi M.

Pediatr Infect Dis J. 2016 Jun;35(6):690-4. doi: 10.1097/INF.0000000000001127.

16.

Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.

Gröndahl-Yli-Hannuksela K, Kauko L, Van Der Meeren O, Mertsola J, He Q.

Vaccine. 2016 Jan 12;34(3):341-9. doi: 10.1016/j.vaccine.2015.11.049. Epub 2015 Nov 29.

PMID:
26643932
17.

Interleukin-10 gene promoter region polymorphisms are not associated with BCG osteitis in vaccinated infants.

Pöyhönen L, Teräsjärvi J, Nuolivirta K, Vuononvirta J, Gröndahl-Yli-Hannuksela K, Kröger L, Huhtala H, Mertsola J, Ilonen J, Peltola V, Korppi M, He Q.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1158-62. doi: 10.5588/ijtld.15.0348.

PMID:
26459526
18.

The Gene Polymorphism of IL-17 G-152A is Associated with Increased Colonization of Streptococcus pneumoniae in Young Finnish Children.

Vuononvirta J, Peltola V, Ilonen J, Mertsola J, He Q.

Pediatr Infect Dis J. 2015 Sep;34(9):928-32. doi: 10.1097/INF.0000000000000691.

PMID:
26376306
19.

Accuracy and feasibility of point-of-care white blood cell count and C-reactive protein measurements at the pediatric emergency department.

Ivaska L, Niemelä J, Leino P, Mertsola J, Peltola V.

PLoS One. 2015 Jun 2;10(6):e0129920. doi: 10.1371/journal.pone.0129920. eCollection 2015.

20.

Toll-like receptor 2 subfamily gene polymorphisms are associated with Bacillus Calmette-Guérin osteitis following newborn vaccination.

Pöyhönen L, Nuolivirta K, Vuononvirta J, Kröger L, Huhtala H, Mertsola J, He Q, Korppi M.

Acta Paediatr. 2015 May;104(5):485-90. doi: 10.1111/apa.12927. Epub 2015 Feb 18.

PMID:
25605403
21.

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.

van Gent M, Heuvelman CJ, van der Heide HG, Hallander HO, Advani A, Guiso N, Wirsing von Kőnig CH, Vestrheim DF, Dalby T, Fry NK, Pierard D, Detemmerman L, Zavadilova J, Fabianova K, Logan C, Habington A, Byrne M, Lutyńska A, Mosiej E, Pelaz C, Gröndahl-Yli-Hannuksela K, Barkoff AM, Mertsola J, Economopoulou A, He Q, Mooi FR.

Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):821-30. doi: 10.1007/s10096-014-2297-2. Epub 2014 Dec 20.

22.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

23.

A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.

Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, Mertsola J, He Q.

J Immunol Methods. 2014 Jun;408:142-8. doi: 10.1016/j.jim.2014.06.001. Epub 2014 Jun 10.

PMID:
24925807
24.

Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.

Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutyńska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR.

MBio. 2014 Apr 22;5(2):e01074. doi: 10.1128/mBio.01074-14.

25.

Editorial commentary: pertussis is less severe in vaccinated than in unvaccinated patients.

Mertsola J.

Clin Infect Dis. 2014 Jun;58(11):1530-2. doi: 10.1093/cid/ciu161. Epub 2014 Mar 14. No abstract available.

PMID:
24633682
26.

Lack of association between mannose binding lectin and antibody responses after acellular pertussis vaccinations.

Gröndahl-Yli-Hannuksela K, Vuononvirta J, Peltola V, Mertsola J, He Q.

PLoS One. 2014 Feb 18;9(2):e88919. doi: 10.1371/journal.pone.0088919. eCollection 2014.

27.

Normal behavior of plasma procalcitonin in adolescents undergoing surgery for scoliosis.

Syvänen J, Peltola V, Pajulo O, Ruuskanen O, Mertsola J, Helenius I.

Scand J Surg. 2014 Mar;103(1):60-5. doi: 10.1177/1457496913504910. Epub 2014 Feb 11.

PMID:
24520101
28.

Risk of repeated Moraxella catarrhalis colonization is increased in children with Toll-like receptor 4 Asp299Gly polymorphism.

Vuononvirta J, Peltola V, Mertsola J, He Q.

Pediatr Infect Dis J. 2013 Nov;32(11):1185-8. doi: 10.1097/INF.0b013e31829e6df2.

PMID:
24141797
29.

Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, von Könnig CH, Riffelmann M, Mooi FR, Sandven P, Lutynska A, Fry NK, Mertsola J, He Q.

J Clin Microbiol. 2013 Feb;51(2):422-8. doi: 10.1128/JCM.02036-12. Epub 2012 Nov 21.

30.

Increased risk of pertussis in adult patients with mannose-binding lectin deficiency.

Gröndahl-Yli-Hannuksela K, Viander M, Mertsola J, He Q.

APMIS. 2013 Apr;121(4):311-5. doi: 10.1111/apm.12000. Epub 2012 Sep 13.

PMID:
23030784
31.

Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.

Barkoff AM, Gröndahl-Yli-Hannuksela K, Vuononvirta J, Mertsola J, Kallonen T, He Q.

Vaccine. 2012 Nov 6;30(48):6897-902. doi: 10.1016/j.vaccine.2012.09.003. Epub 2012 Sep 13.

PMID:
22981763
32.

Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland.

Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q.

Clin Vaccine Immunol. 2012 Oct;19(10):1703-4. Epub 2012 Aug 22. No abstract available.

33.

High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance.

He Q, Barkoff AM, Mertsola J, Glismann S, Bacci S; European Bordetella expert group (EUpertstrain); European surveillance network for vaccine-preventable diseases (EUVAC.NET).

Euro Surveill. 2012 Aug 9;17(32). pii: 20239.

34.

Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR.

Kallonen T, Mertsola J, Mooi FR, He Q.

Clin Microbiol Infect. 2012 Oct;18(10):E377-9. doi: 10.1111/j.1469-0691.2012.04000.x. Epub 2012 Aug 22.

35.

Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence.

Gröndahl-Yli-Hannuksela K, Vuononvirta J, Barkoff AM, Viander M, Van Der Meeren O, Mertsola J, He Q.

J Infect Dis. 2012 Apr 15;205(8):1214-9. doi: 10.1093/infdis/jis182. Epub 2012 Mar 1.

PMID:
22383676
36.

Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants.

Vuononvirta J, Toivonen L, Gröndahl-Yli-Hannuksela K, Barkoff AM, Lindholm L, Mertsola J, Peltola V, He Q.

PLoS One. 2011;6(10):e26198. doi: 10.1371/journal.pone.0026198. Epub 2011 Oct 13.

37.

Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries.

Kallonen T, Gröndahl-Yli-Hannuksela K, Elomaa A, Lutyńska A, Fry NK, Mertsola J, He Q.

Infect Genet Evol. 2011 Dec;11(8):2034-42. doi: 10.1016/j.meegid.2011.09.012. Epub 2011 Sep 21.

PMID:
21964035
38.

Pandemic influenza A (H1N1) virus in households with young children.

Peltola V, Teros-Jaakkola T, Rulli M, Toivonen L, Broberg E, Waris M, Mertsola J.

Influenza Other Respir Viruses. 2012 May;6(3):e21-4. doi: 10.1111/j.1750-2659.2011.00289.x. Epub 2011 Sep 23.

39.

[Lymphadenitis caused by nontuberculous mycobacteriae].

Salo E, Renko M, Koivunen P, Heiskanen-Kosma T, Mertsola J, Nokso-koivisto J, Korppi M.

Duodecim. 2011;127(10):979-86. Finnish.

PMID:
21695996
40.

SNP-based typing: a useful tool to study Bordetella pertussis populations.

van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, Mertsola J, Advani A, Hallander HO, Janssens K, Hermans PW, Mooi FR.

PLoS One. 2011;6(5):e20340. doi: 10.1371/journal.pone.0020340. Epub 2011 May 27.

41.

Rationale for pertussis booster vaccination throughout life in Europe.

Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Van Damme P.

Lancet Infect Dis. 2011 Jul;11(7):557-70. doi: 10.1016/S1473-3099(11)70007-X. Epub 2011 May 18. Review.

PMID:
21600850
42.

Interactions between Bordetella pertussis and the complement inhibitor factor H.

Amdahl H, Jarva H, Haanperä M, Mertsola J, He Q, Jokiranta TS, Meri S.

Mol Immunol. 2011 Jan;48(4):697-705. doi: 10.1016/j.molimm.2010.11.015. Epub 2010 Dec 16.

PMID:
21167605
43.

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.

Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM.

Clin Infect Dis. 2010 Sep 15;51(6):656-62. doi: 10.1086/655825.

PMID:
20704493
44.

[Evaluation of a feverish child].

Ruuskanen O, Saxén H, Mertsola J.

Duodecim. 2009;125(24):2709-14. Review. Finnish.

PMID:
20175324
45.

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence.

Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J.

Emerg Infect Dis. 2009 Aug;15(8):1206-13. doi: 10.3201/eid1508.081511.

46.

Rhinovirus infections in children: a retrospective and prospective hospital-based study.

Peltola V, Jartti T, Putto-Laurila A, Mertsola J, Vainionpää R, Waris M, Hyypiä T, Ruuskanen O.

J Med Virol. 2009 Oct;81(10):1831-8. doi: 10.1002/jmv.21590.

PMID:
19697407
47.

Pertussis before and after the introduction of acellular pertussis vaccines in Finland.

Elomaa A, He Q, Minh NN, Mertsola J.

Vaccine. 2009 Sep 4;27(40):5443-9. doi: 10.1016/j.vaccine.2009.07.010. Epub 2009 Jul 21.

PMID:
19628060
48.

Bordetella pertussis isolates in Finland: serotype and fimbrial expression.

Heikkinen E, Xing DK, Olander RM, Hytönen J, Viljanen MK, Mertsola J, He Q.

BMC Microbiol. 2008 Sep 25;8:162. doi: 10.1186/1471-2180-8-162.

49.

Factors contributing to pertussis resurgence.

He Q, Mertsola J.

Future Microbiol. 2008 Jun;3(3):329-39. doi: 10.2217/17460913.3.3.329. Review.

PMID:
18505398
50.

Local immune response to upper urinary tract infections in children.

Kantele A, Palkola N, Arvilommi H, Honkinen O, Jahnukainen T, Mertsola J, Kantele JM.

Clin Vaccine Immunol. 2008 Mar;15(3):412-7. doi: 10.1128/CVI.00373-07. Epub 2008 Jan 9.

Supplemental Content

Loading ...
Support Center